Patents by Inventor Liangxing Wu

Liangxing Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20220213090
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: September 24, 2021
    Publication date: July 7, 2022
    Inventors: Liangxing Wu, Neil Lajkiewicz, Chunhong He, Kaijiong Xiao, Wenyu Zhu, Zhenwu Li, Song Mei, Chao Qi, Leah C. Konkol, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20220194931
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 23, 2022
    Inventors: Liangxing Wu, Jingwei Li, Chao Qi, Fenglei Zhang, Zhenwu Li, Wenyu Zhu, Zhiyong Yu, Kaijiong Xiao, Liang Lu, Song Mei, Ding-Quan Qian, Chunhong He, Yingda Ye, Meizhong Xu, Wenqing Yao
  • TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS
    Publication number: 20220169649
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: July 1, 2021
    Publication date: June 2, 2022
    Inventors: Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Heterocyclic compounds as immunomodulators
    Patent number: 11339149
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: May 24, 2022
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Jingwei Li, Wenqing Yao, Chao Qi, Ding-Quan Qian, Fenglei Zhang
  • FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS
    Publication number: 20220135570
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: October 13, 2021
    Publication date: May 5, 2022
    Inventors: Xiaozhao Wang, Peter Niels Carlsen, Pei Gan, Gia Hoang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Wenyu Zhu
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20220089588
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: May 4, 2021
    Publication date: March 24, 2022
    Inventors: Liangxing Wu, Fenglei Zhang, Song Mei, Wenqing Yao
  • TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS
    Publication number: 20220073509
    Abstract: The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: March 2, 2021
    Publication date: March 10, 2022
    Inventors: Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
  • TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS
    Publication number: 20220064165
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: August 26, 2021
    Publication date: March 3, 2022
    Inventors: Kai Liu, Brent Douty, Daniel Levy, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS
    Publication number: 20220056049
    Abstract: The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: January 6, 2020
    Publication date: February 24, 2022
    Inventors: Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 11247992
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: February 15, 2022
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Xiaozhao Wang, Wenqing Yao, Fenglei Zhang
  • PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20220017521
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and/or FGFR activity, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity and/or FGFR activity, such as cancer.
    Type: Application
    Filed: August 4, 2021
    Publication date: January 20, 2022
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Liangxing Wu, Wenqing Yao, Peng Zhao
  • BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
    Publication number: 20220009921
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Application
    Filed: April 23, 2021
    Publication date: January 13, 2022
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
  • DIHYDROPYRIDO[2,3-D]PYRIMIDINONE COMPOUNDS AS CDK2 INHIBITORS
    Publication number: 20220009923
    Abstract: The present application provides dihydropyrido[2,3-d]pyrimidone inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: June 10, 2021
    Publication date: January 13, 2022
    Inventors: Alexander Sokolsky, Liangxing Wu, Wenqing Yao
  • TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS
    Publication number: 20220002299
    Abstract: The present application provides tricyclic pyridone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: July 1, 2021
    Publication date: January 6, 2022
    Inventors: Kai Liu, Onur Atasoylu, Yu Bai, Andrew W. Buesking, Leah C. Konkol, Cheng-Tsung Lai, Song Mei, Jun Pan, Liangxing Wu, Wenqing Yao
  • PYRROLOTRIAZINE COMPOUNDS AS JAK2 V617F INHIBITORS
    Publication number: 20210395257
    Abstract: The present application provides pyrrolotriazine compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: June 17, 2021
    Publication date: December 23, 2021
    Inventors: Zhiyong Yu, Liangxing Wu, Wenqing Yao
  • BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20210395246
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: January 28, 2021
    Publication date: December 23, 2021
    Inventors: Yaping Sun, Liang Lu, Wenqing Yao, Jincong Zhuo, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Chunhong He, Fenglei Zhang
  • NAPHTHYRIDINONE COMPOUNDS AS JAK2 V617F INHIBITORS
    Publication number: 20210395251
    Abstract: The present application provides naphthyridinone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: June 17, 2021
    Publication date: December 23, 2021
    Inventors: Stacey Shepard, Lixin Shao, Liangxing Wu, Wenqing Yao
  • IMIDAZOPYRIDAZINE COMPOUNDS AND USES THEREOF
    Publication number: 20210388003
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
    Type: Application
    Filed: June 10, 2021
    Publication date: December 16, 2021
    Inventors: Jun Pan, Yu Bai, Liangxing Wu, Wenqing Yao
  • SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
    Publication number: 20210380587
    Abstract: The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: June 2, 2021
    Publication date: December 9, 2021
    Inventors: Liangxing Wu, Colin Zhang, Chunhong He, Liang Lu, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20210380584
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: August 18, 2021
    Publication date: December 9, 2021
    Inventors: Liangxing Wu, Jingwei Li, Wenqing Yao